Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HPGDS | O60760 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3316329 | 1.00 | HRH3 (0.39) | HRH3ALDH1A1KDM4EMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL25233214 | 0.97 | ALDH1A1 (0.38) | HRH3ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL5314785 | 0.97 | LMNA (0.36) | HRH3ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL4542873 | 0.91 | — | — | |
| Formic Acid SCHEMBL14969699 | 0.86 | HSD17B10 (0.37) | HRH3ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL25235628 | 0.84 | KDM1A (0.34) | KMT2ALMNAKDM1ADRD2 | |
| Hydrochloric Acid SCHEMBL25234812 | 0.81 | KDM1A (0.33) | KDM1ADRD2 | |
| SCHEMBL30341319 | 0.81 | KDM4E (0.31) | ALDH1A1KDM4E | |
| SCHEMBL12391108 | 0.78 | ALDH1A1 (0.36) | HRH3ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL31265278 | 0.78 | ALDH1A1 (0.41) | HRH3ALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | NOVARTIS PHARMA AG (CH) | 2025-12-23 | — | — | US | claimed |
| US-12404283-B2 | c-MYC mRNA translation modulators and uses thereof in the treatment of cancer | ANIMA BIOTECH INC. (US) | 2025-09-02 | — | — | US | claimed |
| EP-4547672-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| US-20250129100-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-04-24 | — | — | US | claimed |
| WO-2025008783-A1 | PHARMACEUTICAL COMPOSITION COMPRISING 1,3-BENZODIOXOLE DERIVATIVE COMPOUND | 동화약품주식회사 | 2025-01-09 | — | — | WO | claimed |
| WO-2024010762-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2024-01-11 | — | — | WO | claimed |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | claimed |
| WO-2023135564-A1 | 1,3-BENZODIOXOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 동화약품주식회사 | 2023-07-20 | — | — | WO | claimed |
| US-11661421-B2 | Indolizine compounds, preparation method and use thereof | HAIHE BIOPHARMA CO., LTD. (CN) | 2023-05-30 | — | — | US | claimed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | claimed |
| WO-2010009166-A1 | OXINDOLYL INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-01-21 | — | — | WO | claimed |
| WO-2010009139-A2 | IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-01-21 | — | — | WO | claimed |
| WO-2010009155-A2 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-01-21 | — | — | WO | claimed |
| US-20100009990-A1 | IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-01-14 | — | — | US | claimed |
| US-20090005374-A1 | IMIDAZOPYRIDINYL THIAZOLYL HISTONE DEACETYLASE INHIBITORS | GILEAD SCIENCES, INC. | 2009-01-01 | — | — | US | claimed |
| WO-2009002534-A1 | IMIDAZOPYRIDINYL THIAZOLYL HISTONE DEACETYLASE INHIBITORS | GILEAD COLORADO, INC. (US) | 2008-12-31 | — | — | WO | claimed |
| EP-0809499-A4 | CERTAIN 1,4,5-TRI-SUBSTITUTED IMIDAZOLE COMPOUNDS USEFUL AS CYTOKINE | SMITHKLINE BEECHAM CORP (US) | 1998-10-14 | — | — | EP | claimed |
| CN-1177299-A | Certain 1, 4, 5 -tri- substituted imidazole compounds useful as cytokine | SMITHKLINE BEECHAM CORP (US) | 1998-03-25 | — | — | CN | claimed |
| EP-0809499-A1 | CERTAIN 1,4,5-TRI-SUBSTITUTED IMIDAZOLE COMPOUNDS USEFUL AS CYTOKINE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-03 | — | — | EP | claimed |
| WO-1996021452-A1 | CERTAIN 1,4,5-TRI-SUBSTITUTED IMIDAZOLE COMPOUNDS USEFUL AS CYTOKINE | SMITHKLINE BEECHAM CORPORATION (US) | 1996-07-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | HRH3 4374/4885ALDH1A1 1243/4885KDM4E 2746/4885 |
| US-11661421-B2 | Indolizine compounds, preparation method and use thereof | EZH1, EZH2, IKZF3 | HRH3 166/4885ALDH1A1 2385/4885KDM4E 61/4885 |
| US-20100009990-A1 | IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS | HDAC1, CDK9, CDK2 | HRH3 1138/4885ALDH1A1 1714/4885KDM4E 532/4885 |
| US-20090005374-A1 | IMIDAZOPYRIDINYL THIAZOLYL HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC8, HDAC5 | HRH3 804/4885ALDH1A1 1787/4885KDM4E 333/4885 |
| US-20250129100-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | HRH3 4838/4885ALDH1A1 4445/4885KDM4E 1350/4885 |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, CGAS, IRF3 | HRH3 1666/4885ALDH1A1 4654/4885KDM4E 3761/4885 |
| US-12404283-B2 | c-MYC mRNA translation modulators and uses thereof in the treatment of cancer | MYC, MYCBP, MYCBP2 | HRH3 4838/4885ALDH1A1 4445/4885KDM4E 1350/4885 |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | HBZ, ZFX, WIZ | HRH3 4374/4885ALDH1A1 1243/4885KDM4E 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.